Chemomab Therapeutics (CMMB) Earnings Date & Reports

Key Takeaways

• Chemomab Therapeutics is expected to report third quarter 2026 financial results before the market opens on November 6, 2026.
• As a clinical-stage biotechnology company, Chemomab generates no product revenue, so investors will focus on spending, cash runway, and pipeline milestones rather than top-line sales.
• Wall Street consensus models a net loss of roughly $0.01 per share, reflecting the company's pre-revenue operating profile.
• Cash, cash equivalents, and short-term bank deposits stood at $6.7 million as of June 30, 2026, with management guiding that existing liquidity funds operations into the first quarter of 2027.
• The proposed merger with precision medicine company Scipher Medicine, announced in July 2026, and the advancement of lead candidate nebokitug remain central themes heading into the report.
• For more context on the company, readers can explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
• Investors seeking automated market ideas may also want to explore Trending AI Robots.

Earnings Context and Why It Matters

For Chemomab Therapeutics (CMMB), a clinical-stage biopharmaceutical firm developing treatments for fibro-inflammatory diseases, quarterly earnings are less about revenue and more about financial durability and execution. The company's lead asset, nebokitug, is a monoclonal antibody that targets CCL24, a protein linked to fibrosis and inflammation, with a lead indication in primary sclerosing cholangitis (PSC), a rare liver disease. Following positive Phase 2 data, Chemomab is preparing for a potential Phase 3 trial, while a July 2026 merger agreement with Scipher Medicine adds an AI-driven Phase 2 study in rheumatoid arthritis. Against this backdrop, the third quarter report offers a key checkpoint on cash management and R&D (research and development) progress.

Earnings Expectations

Analysts expect Chemomab to report a modest net loss, with consensus estimates pointing to a loss of approximately $0.01 per share for the third quarter of 2026. Because the company has no approved product, revenue is not a meaningful metric; instead, investors will scrutinize operating expenses, particularly R&D and G&A (general and administrative) spending. In the second quarter of 2026, R&D expenses were $1.1 million and G&A expenses were $1.1 million, yielding a net loss of about $2.2 million. Historical results show consistent quarterly losses, with the most recent quarters improving slightly on a per-share basis as share counts rose. The key figures to watch are the reported net loss, cash balance, and any update to the company's stated cash runway through the first quarter of 2027.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking names like Chemomab Therapeutics, the AI Screener offers a structured way to surface ideas across the biotechnology sector.

Market Reaction and Investor Sentiment

Sentiment heading into the third quarter report is shaped less by earnings-per-share figures than by strategic developments. Shares of this small-cap biotech have been volatile, reflecting both the binary nature of clinical-stage investing and the company's thin cash position. The announced merger with Scipher Medicine and plans for a Phase 3 nebokitug trial in PSC have provided forward-looking catalysts, but investors remain attentive to financing risk. A narrowing loss or confirmation of the cash runway through early 2027 would likely be viewed favorably, while any indication of accelerated spending or a shortened runway could weigh on the stock. Trading volume is relatively light, which can amplify price moves around earnings.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors should monitor several items closely. First, any update on the cash runway is critical. With $6.7 million in cash as of June 30, 2026, the company has guided that it can fund operations into the first quarter of 2027, but a clinical-stage firm preparing a Phase 3 trial will likely need additional capital.

Second, the progress of the Scipher Medicine merger is a central storyline. Successful integration and the initiation of an AI-powered Phase 2 study of nebokitug in rheumatoid arthritis could expand the pipeline and potentially strengthen the company's position ahead of the planned Phase 3 PSC trial.

Third, watch for any updates on the Phase 3 PSC trial design and regulatory interactions. Nebokitug already holds Orphan Drug designations from the FDA (U.S. Food and Drug Administration) and EMA (European Medicines Agency) as well as FDA Fast Track status for PSC, which may streamline development. Finally, monitor expense trends, as disciplined spending will help extend the runway while the company advances its clinical programs. As always, clinical-stage investing carries meaningful risk, and outcomes will depend heavily on trial results and financing execution.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations